SCHEMBL23629612

SCHEMBL23629612

O=C1CC[C@@H](COC(=O)c2ccccc2)N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.47
CHRNA5 P30532 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47
PPM1B O75688 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
KMT2A Q03164 2/20 0.43
CES2 O00748 1/20 0.43
MEN1 O00255 1/20 0.43
ATM Q13315 1/20 0.43
MAPK1 P28482 1/20 0.42
HIF1A Q16665 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PDK2 Q15119 3/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25694068 1.00 CHRNB2 (0.47) CHRNB2CHRNA5CHRNA7CHRNA4PPM1B
SCHEMBL17505922 0.95 CHRNB2 (0.43) CHRNB2CHRNA5CHRNA7CHRNA4PPM1B
SCHEMBL9994588 0.79 MGLL (0.40) PDK2IRAK4
SCHEMBL9994585 0.77 MGLL (0.41) PDK2IRAK4
SCHEMBL18014832 0.77 PDK2 (0.40) MAPK1PDK2IRAK4
SCHEMBL26507782 0.76 ALPI (0.44) PDK2IRAK4
SCHEMBL2366102 0.75 PPM1B (0.46) CHRNB2CHRNA5CHRNA7CHRNA4PPM1B
SCHEMBL2366108 0.75 PPM1B (0.46) CHRNB2CHRNA5CHRNA7CHRNA4PPM1B
SCHEMBL9453170 0.75 PPM1B (0.46) CHRNB2CHRNA5CHRNA7CHRNA4PPM1B
SCHEMBL6920902 0.75 PDK2 (0.43) KMT2APDK2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066296-A1 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2025-02-27 US disclosed
EP-4448490-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF Alexion Pharmaceuticals, Inc. (US) 2024-10-23 EP disclosed
US-11814363-B2 Morphic forms of danicopan ACHILLION PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 WO disclosed
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 WO disclosed
US-20230094124-A1 MORPHIC FORMS OF DANICOPAN ACHILLION PHARMACEUTICALS, INC. (US) 2023-03-30 US disclosed
EP-3847174-A1 MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS Achillion Pharmaceuticals, Inc. (US) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066296-A1 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF CFD, CFH, CFB CHRNB2 4837/4885CHRNA5 4874/4885CHRNA7 4869/4885
US-20230094124-A1 MORPHIC FORMS OF DANICOPAN CFD, CFH, C9 CHRNB2 3892/4885CHRNA5 4679/4885CHRNA7 4515/4885
US-11814363-B2 Morphic forms of danicopan CFD, CFH, C9 CHRNB2 4000/4885CHRNA5 4568/4885CHRNA7 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.